Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL-018 in Moderate to Severe Active Rheumatoid Arthritis
NCT07748728Phase 2Enrolling by invitation
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of girocitinib in rheumatoid arthritis (RA), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd.. Started Sep 2026; status: enrolling by invitation.
02
Drugs
girocitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07748728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748728.